Loading search results
Effectiveness of a Telehealth Educational Intervention on Glycemic Control, Medication Adherence, and Quality of Life Among Adults With Type 2 Diabetes in Oman: Study Protocol for a Two-Arm Parallel Randomized Controlled Trial
Sponsor study identifier
interventional
160
1 country
1
Study Start
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
November 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
January 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this clinical trial is to find out whether adding a nurse-led telehealth educational program to usual diabetes care can improve blood sugar control, medication-related behaviors, and quality of life in adults with type 2 diabetes in Oman. The main question this study aims to answer is whether adults who receive the telehealth educational program, in addition to their usual diabetes care, have better blood sugar control after 6 months than adults who receive usual diabetes care alone. Blood sugar control will be assessed using hemoglobin A1c (HbA1c), a blood test that reflects average blood sugar levels over the previous few months. The study will also examine whether the telehealth program improves participants' attitudes and behaviors related to taking their diabetes medicines and their diabetes-related quality of life. Among participants receiving the telehealth intervention, the study will also assess how easy, useful, reliable, and satisfactory they find the telehealth service. Approximately 160 Omani adults with type 2 diabetes will take part in the study. Participants will be randomly assigned to one of two groups. One group will continue usual diabetes care and will also receive an individual telehealth education session once a week for 24 weeks. Each session will last about 20 to 30 minutes and will be provided by a trained nurse using an approved secure telehealth platform. The sessions will cover topics such as diabetes and HbA1c, safe use of medicines, strategies for remembering medicines, healthy eating, physical activity, blood glucose monitoring, recognition of low and high blood sugar, prevention of diabetes complications, stress and sleep, and communication with healthcare professionals. The other group will continue to receive usual diabetes care without the additional study telehealth education program. No established diabetes care will be withheld from either group, and the telehealth education will not replace routine medical care or authorize the research team to change participants' medications. Participants will be assessed at the start of the study, at 3 months, and at 6 months. Assessments will include HbA1c testing and questionnaires about medication-related beliefs and behaviors and diabetes-related quality of life. Participants in the telehealth group will also complete a questionnaire about their experience with and satisfaction with telehealth.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 25, 2026
Actual (reported)August 28, 2026
Actual (reported)November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
November 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
January 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Change in Hemoglobin A1c (HbA1c) From Baseline to 6 Months
Measure: Change in Hemoglobin A1c (HbA1c) Description: HbA1c will be measured as a continuous percentage. The primary treatment effect is the adjusted between-group difference in change from baseline to month 6.
Baseline to 6 months
Change in Hemoglobin A1c (HbA1c)
HbA1c will be measured as a continuous percentage. The primary treatment effect is the adjusted between-group difference in change from baseline to month 6.
Baseline to month 6.
Change in Positive Attitudes Towards Healthcare and Medication Score From Baseline to 6 Months
Baseline to 6 Months
Change in Diabetes-Specific Quality of Life From Baseline to 6 Months
From Baseline to 6 Months
Change in Medication-Adherence Beliefs and Behaviors
Assessed at baseline, 3 months, and 6 months.
Telehealth Usability and Satisfaction
at months 3 and 6
Participants will continue usual diabetes care and receive one individual synchronous telehealth education session each week for 24 weeks. Sessions will generally last 20-30 minutes and will be delivered in Arabic or English by a trained diabetes nurse educator or research nurse using an institutionally approved secure platform. The first 12 weeks will follow a standardized diabetes education curriculum, and weeks 13-24 will reinforce content, review personal goals, address barriers, and revisit topics as needed. The intervention is educational; research staff will not initiate, discontinue, or adjust medications.
This group continues established usual diabetes care at SQUH, including routine clinic review, medication management, laboratory testing, and standard education.
Participants assigned to the intervention group will receive usual diabetes care plus one individual synchronous telehealth education session each week for 24 weeks. Sessions will generally last 20-30 minutes and will be delivered in Arabic or English by a trained diabetes nurse educator or research nurse using an SQU/SQUH-approved secure platform. Video will be encouraged when feasible; secure audio may be used if connectivity is insufficient. The first 12 weeks will follow a standardized curriculum covering diabetes and HbA1c, medication use and adherence strategies, healthy eating, physical activity, glucose monitoring, hypo- and hyperglycemia, complication prevention, stress and sleep, communication with healthcare professionals, and maintenance planning. Weeks 13-24 will reinforce content, review goals, address barriers, and revisit topics as needed. Research staff will not initiate, discontinue, or adjust medications; clinical questions will be referred to the treating team.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Sultan Qaboos University Hospital
Muscat, Al Khoud, 123, Oman
Nahla Mansour Al Aali, PhD
College of Nursing, Sultan Qaboos University
First Submitted
August 25, 2026
First Posted
August 28, 2026
Study Start
November 1, 2026
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
November 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
January 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 28, 2026
Record last verified: 2026-08
De-identified individual participant data and analysis code may be shared after publication of the primary study findings upon reasonable request. Access will be subject to approval by the principal investigator, relevant institutional and ethics authorities, and completion of an appropriate data-use agreement.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: